Joint & Vascular Institute is proud to announce participation in an FDA-approved Investigational Device Exemption (IDE) clinical trial evaluating Plantar Fasciitis Embolization (PFE) for patients suffering from chronic heel pain caused by plantar fasciitis.
Plantar fasciitis is one of the most common causes of persistent heel pain and affects approximately one million individuals in the United States each year.
While many patients respond to conservative therapies such as orthotics, physical therapy, or injections, a subset experience long-term, treatment-resistant symptoms that significantly impact mobility and quality of life.
This IDE trial is designed to evaluate the safety and effectiveness of minimally invasive plantar fascia embolization, an image-guided outpatient procedure that works by targeting abnormal neovascularity associated with chronic inflammation in the plantar fascia.
Eligible participants will undergo embolization to reduce inflammation and improve foot function, with outcomes measured over a structured follow-up period. Current endpoints include:
• Reduction in heel pain
• Improvement in foot and ankle function
• Procedural safety and recovery outcomes (ClinicalTrials.gov)
Patients interested in learning more about eligibility criteria, study requirements, or enrollment opportunities can review the full trial details below: